Evidence map›Paper›PMID 41306720›Full record

ArticleEFSA journal. European Food Safety Authority2025

Modification of the existing maximum residue levels in barley, wheat and rye, and evaluation of Art.12 confirmatory data for pinoxaden.

European Food Safety Authority (EFSA), Giulia Bellisai, Giovanni Bernasconi, Luis Carrasco Cabrera, Irene Castellan, Monica Del Aguila, Lucien Ferreira, Luna Greco, Renata Leuschner, Andrea Mioč and 9 more

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

European Food Safety Authority (EFSA)
Giulia Bellisai
Giovanni Bernasconi
Luis Carrasco Cabrera
Irene Castellan
Monica Del Aguila
Lucien Ferreira
Luna Greco
Renata Leuschner
Andrea Mioč
Stefanie Nave
Hermine Reich
Silvia Ruocco
Alessia Pia Scarlato
Marta Szot
Anne Theobald
Manuela Tiramani
Alessia Verani
Elena Zioga

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Syngenta Crop Protection AG submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) in barley, wheat and rye for pinoxaden. The data submitted in support of the requests were found to be sufficient to derive an MRL proposal. Adequate analytical methods for enforcement are available to control the residues of M4 (SYN 505164) and M6 (SYN 502836), the metabolites of pinoxaden included in the residue definitions in cereal grains, individually at a validated limit of quantification (LOQ) of 0.01 mg/kg. Additionally, in a separate application submitted to Italy as well, the applicant requested the evaluation of the confirmatory data identified during the MRL review conducted under Article 12 of Regulation (EC) No 396/2005 as not available. To address the MRL review data gap, a new confirmatory analytical methodology for animal matrices was submitted. This data gap was considered satisfactorily addressed. The information provided did not require a revision of the existing MRLs in products of animal origin, which are confirmed. Based on the risk assessment results, EFSA concluded that the short-term and long-term intake of residues resulting from the uses of pinoxaden according to the reported agricultural practices is unlikely to present a risk to consumer health.

Indexed as

cerealsconfirmatory dataconsumer risk assessmentMRLpesticidepinoxaden

Identifiers

PMID41306720
PMCPMC12645058

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.